Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ultragenyx Pharmaceutical Inc RARE

Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product... see more

Recent & Breaking News (NDAQ:RARE)

Ultragenyx Announces First Patient Dosed in Pivotal Phase 2/3 Clinical Study of Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta

GlobeNewswire April 20, 2022

Ultragenyx to Participate in the Cowen Health Care Conference

GlobeNewswire March 2, 2022

Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

GlobeNewswire February 10, 2022

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2021 Financial Results and Corporate Update

GlobeNewswire February 3, 2022

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 2, 2022

Ultragenyx Reports Preliminary 2021 Revenue and 2022 Revenue Guidance for Crysvita® in Ultragenyx Territories* And Dojolvi® Globally; Provides Pipeline Updates and 2022 Milestones

GlobeNewswire January 10, 2022

Ultragenyx to Present at H.C. Wainwright BioConnect Healthcare Conference

GlobeNewswire January 6, 2022

GeneTx and Ultragenyx Provide Preliminary Update on Phase 1/2 Clinical Study of GTX-102 in Canada and U.K. Patients with Angelman Syndrome

GlobeNewswire January 5, 2022

Ultragenyx to Present at 40th Annual JP Morgan Healthcare Conference

GlobeNewswire January 3, 2022

GeneTx and Ultragenyx Announce Presentations at Upcoming 2021 FAST Global Summit & Gala

GlobeNewswire December 1, 2021

Ultragenyx Announces First Patient Dosed in Phase 1/2 Clinical Study of UX053, an mRNA Therapy for the Treatment of Glycogen Storage Disease Type III

GlobeNewswire December 1, 2021

Ultragenyx to Present at Evercore 4th Annual HealthconX Conference

GlobeNewswire November 29, 2021

Ultragenyx Announces Additional Positive Multi-Year Durability Data from Phase 1/2 AAV Gene Therapy Studies

GlobeNewswire November 29, 2021

Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate Update

GlobeNewswire November 2, 2021

Ultragenyx to Host Conference Call for Third Quarter 2021 Financial Results and Corporate Update

GlobeNewswire October 26, 2021

Ultragenyx to Present at Jefferies Gene Therapy/Editing Summit

GlobeNewswire October 25, 2021

Ultragenyx Initiates Cyprus2+, a Pivotal Clinical Trial Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease

GlobeNewswire October 18, 2021

GeneTx and Ultragenyx Announce First Patient Dosed in Canada in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome

GlobeNewswire October 7, 2021

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 4, 2021

Mereo BioPharma and Ultragenyx Present Data from the Phase 2b ASTEROID Study of UX143 (setrusumab) in Osteogenesis Imperfecta (OI) at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting

GlobeNewswire October 1, 2021